BioSpace News Archive

The cluster headache market is estimated to experience significant growth opportunities in the upcoming years.

Fact.MR – A Market Research and Competitive Intelligence Provider: As per Fact.MR, the global fluoroscopy equipment market size is estimated to exceed US$ 1.9 Bn in 2021.

The ataxia market has been anticipated to experience noteworthy growth prospects in the forthcoming years.

Hørsholm, Denmark – Allarity Therapeutics A/S announced positive results from the further pre-clinical testing of the antiviral activity of its oral PARP inhibitor, stenoparib, against Coronavirus variant B.1.617.2.

Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, shared preclinical data at the Society for Immunotherapy of Cancer’s 36th Annual Meeting.

CrestOptics S.p.A., a manufacturer of high-end microscopy solutions and advanced systems for fluorescence microscopy and diagnostic applications, announced it has been acquired through a majority shareholding by Apposite Capital LLP, the healthcare specialist private equity investor.

Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum being held virtually November 18, 2021.

RenovoRx, Inc., a biopharmaceutical company and innovator in targeted cancer therapy, announced that it will be presenting an ePoster at the 2021 Pancreas Club Annual Meeting being held virtually on November 11-12, 2021.

Notable Labs, Inc., a pioneer and developer of predictive precision medicines, has obtained worldwide rights to volasertib from Oncoheroes Biosciences Inc., a Boston-based biotechnology company focused on advancing new therapies for childhood cancer.

Dermata Therapeutics, Inc., a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, announced it will host a virtual investor event to present the DMT410 Phase 1b results in multiple aesthetic skin conditions on Friday, November 19, 2021 at 4:30 pm ET.